Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 16/20 | 0.48 |
| ▸ | SCN1A | P35498 | 3/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20095635 | 1.00 | SCN9A (0.48) | SCN9ASCN1ASCN5ASCN8AUSP2 | |
| SCHEMBL20072811 | 1.00 | SCN9A (0.48) | SCN9ASCN1ASCN5ASCN8AUSP2 | |
| SCHEMBL20063794 | 0.91 | SCN9A (0.59) | SCN9A | |
| SCHEMBL20063791 | 0.91 | SCN9A (0.59) | SCN9A | |
| SCHEMBL21905149 | 0.91 | SCN9A (0.59) | SCN9A | |
| SCHEMBL20063789 | 0.91 | SCN9A (0.59) | SCN9A | |
| SCHEMBL20072816 | 0.91 | SCN9A (0.59) | SCN9A | |
| SCHEMBL20095997 | 0.91 | SCN9A (0.59) | SCN9A | |
| SCHEMBL21904010 | 0.88 | SCN9A (0.45) | SCN9A | |
| SCHEMBL20063782 | 0.88 | SCN9A (0.45) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SCN9A 1501/4885SCN1A 619/4885SCN5A 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.